Safety and efficacy established in pediatric patients 317 years of age Safety and effectiveness in patients < 3 years have not been established. Dosing for pediatric patients is determined by body surface area for peginterferon alfa-2b and by body weight for ritonavir An open-label study in patients 3 - 17 years showed weight and height gain of pediatric patients treated with combination therapy lags behind that predicted by population data while on treatment. Adverse events similar to those observed in adults. Most common pediatric adverse events were pyrexia, headache, neutropenia, fatigue, anorexia, injection site erythema, vomiting Information on PK parameters, and clinical study New indication
|